20 articles
Baxdrostat blocks aldosterone production directly, cutting systolic BP by ~15 mmHg in resistant hypertension patients who failed other drugs.
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
Auvelity becomes the first non-antipsychotic approved for Alzheimer's agitation, offering patients and caregivers a safer alternative.
Novel medication lowers stubborn blood pressure by 5% and reduces kidney damage markers by 55% in patients with chronic kidney disease.
Auvelity becomes the first non-antipsychotic FDA-approved treatment for agitation in Alzheimer's dementia, offering a new option for patients and caregivers.
Bemotrizinol, long used safely in Europe, is now FDA-approved for US sunscreens, offering broad UVA and UVB protection with low skin absorption.
A BET inhibitor called RVX-208 reprogrammed diseased perivascular fat, restoring blood vessel function in obese hypertensive patients.
ACD856 crosses the blood-brain barrier and boosts cognition-linked pathways. Phase Ib is complete, with Phase II for Alzheimer's on the horizon.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
UC Davis scientists created novel brain-healing molecules that activate key serotonin receptors tied to neuroplasticity — without triggering hallucinations.
ACD856 cleared a Phase Ib safety trial with no adverse findings, advancing a promising brain-repair drug toward Phase II studies in 2026.
Annovis's buntanetap reduced tau and neuroinflammation markers while improving cognition in mild Alzheimer's patients across a 12-week trial.
Researchers created modified psilocin that maintains antidepressant effects while dramatically reducing psychedelic side effects in mice.
A 50,000-patient study finds same-day gabapentin after TBI cuts cognitive impairment risk by 22% and mortality by 46% in severe cases.
New research finds GLP-1 receptor agonists may dramatically cut age-related macular degeneration risk compared to other medications.
A polypill combining three BP drugs slashed recurrent stroke risk from 7.4% to 4.6% in hemorrhagic stroke survivors, per a New England Journal study.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
